<DOC>
	<DOCNO>NCT02582905</DOCNO>
	<brief_summary>Preclinical clinical data well mechanistic justification present suggest citicoline pregnenolone promise treatment alcohol use BPD . Both appear favorable side effect profile know drug-drug interaction . Thus , potential safely use dual diagnosis population already take medication . A 12-week , randomize , double-blind , parallel-group , placebo-controlled adaptive design study citicoline pregnenolone propose 199 person alcohol use disorder bipolar I II disorder , mood state currently depress . The primary aim ass change alcohol use . Biomarkers alcohol use , alcohol craving , mood cognition also assess . Relationships neurosteroid choline level outcome measure explore .</brief_summary>
	<brief_title>Clinical Medication Development Bipolar Disorder Alcohol Use Disorders</brief_title>
	<detailed_description>A 12-week , randomize , double-blind , parallel-group , placebo-controlled adaptive , Drop The Loser ( DTL ) design clinical trial citicoline pregnenolone conduct 199 outpatient bipolar I II disorder , depress mood state current alcohol use disorder . Potential participant identify appointment arrange . At appointment , informed consent obtain , assessment procedure , include review inclusion exclusion criterion , perform . A structured clinical interview Diagnostic Statistical Manual ( DSM-5 ) , Structured Clinical Interview Disorders ( SCID ) perform establish diagnosis bipolar I II disorder alcohol use disorder . Recent alcohol use ( , present , substance use ) assess use Timeline Followback ( TLFB ) method . Drinking severity withdrawal symptom assess variety measure ( e.g. , Clinical Institute Withdrawal Assessment Alcohol Use-Revised ( CIWA-Ar ) , Penn Alcohol Craving Scale ( PACS ) , Short Index Problems ( SIP ) ) . Length problem alcohol use assess ask `` When alcohol first start cause problem ? '' Blood drawn laboratory analysis include complete blood count ( CBC ) Comprehensive Metabolic Panel ( include liver panel AST , ALT well lipids electrolyte ) , GGT carbohydrate-deficient transferrin ( CDT ) add baseline ( week 0 ) week 6 12 . Cognition , include domain memory , decision making , impulsivity , attention , executive functioning also assess baseline week 12 use World Health Organization/University California Los Angeles Auditory-Verbal Learning Test ( WHO-UCLA AVLT ) , Trail Making Test ( TMT ) , Golden Stroop Color Word Test . Women childbearing potential receive urine pregnancy test baseline , week 6 , week 12 counsel effective contraceptive method . A psychiatrist ( PI Co-I ) ass participant baseline weekly follow-up visit participate informed consent process . The active medication placebo capsule initiate baseline increase weekly week 1 , 2 3 achieve target dos citicoline ( 2000 mg/day ) pregnenolone ( 500 mg/day ) . Side effect manage blinded fashion . Safety side effect assess Systematic Assessment Treatment Emergent Events ( SAFTEE ) . At weekly visit , mood suicidality assess various measure ( e.g . Hamilton Rating Scale Depression ( HRSD17 ) , Columbia Suicide Severity Rating Scale ( CSSRS ) assessment alcohol use evaluate . All participant receive Medical Monitoring ( MM ) psychosocial platform . After study completion , participant provide standard psychiatric care outside referral arranged .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Cytidine Diphosphate Choline</mesh_term>
	<criteria>Outpatient men woman age 1865 year old bipolar I II disorder ( currently depress ) English Spanish speaking Current diagnosis alcohol use disorder least moderate severity ( DSM5 terminology ) Alcohol use least 28 drink week male average 21 drink per week female 3 drinking day week 28 day prior intake Current mood stabilizer therapy ( defined lithium , lamotrigine , carbamazepine , oxcarbazepine atypical antipsychotic ) stable dose ≥ 28 day prior randomization valproate/divalproex stable dose ≥ 90 day ( long period due data suggest valproate may decrease alcohol use BPD ) Diagnosis substance use disorder alcohol , caffeine nicotine allow 1 ) alcohol selfidentified substance choice 2 ) severity substance use disorder ≤ moderate Mood disorder bipolar I II disorder anxiety disorder allow Baseline HRSD17 YMRS score ≥ 35 exclude severe mood symptom baseline Evidence clinically significant alcohol withdrawal symptom define CIWAAr score ≥ 10 Current ( last 28 day ) treatment naltrexone , acamprosate , disulfiram , topiramate may also decrease alcohol use Oral contraceptive hormone replacement therapy . This exclusion due possible interaction pregnenolone . Women hormone sensitive condition breast cancer , uterine cancer , ovarian cancer , endometriosis , uterine fibroid . These person exclude pregnenolone convert estrogen . Vulnerable population ( e.g . pregnant , nursing , cognitively impaired , incarcerate ) High risk suicide define &gt; 1 attempt past 12 month require medical attention , attempt past 3 month current suicidal ideation plan intent outpatient care preclude Intensive outpatient treatment ( define ≥3 visit week ) substance abuse ( AA , NA meeting , less intensive counseling baseline allow ) Severe/unstable condition ( e.g . cirrhosis , poorly control hypertension ) laboratory/physical exam finding consistent serious illness ( e.g . abnormal electrolyte ) AST ALT &gt; 3 time normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alcohol Use Disorder</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Mood</keyword>
	<keyword>Alcohol craving</keyword>
	<keyword>Pregnenolone</keyword>
	<keyword>Citicoline</keyword>
</DOC>